» Articles » PMID: 29209563

Comparative Immunologic Characterization of Autoimmune Giant Cell Myocarditis with Ipilimumab

Abstract

Autoimmune myocarditis is a rare but often fatal toxicity of checkpoint inhibitor immunotherapy. To improve the understanding of this complication, we performed immune profiling on post-mortem tissue from a patient with metastatic melanoma who had steroid-responsive hepatitis, steroid-refractory myocarditis, and shrinking lung metastases after ipilimumab treatment. Histological analysis of heart tissue demonstrated findings consistent with giant cell myocarditis (GCM). The immune infiltrate in the heart was largely comprised of CD4+ T cells, whereas the liver had very few T cells, and CD8+ T cells were predominant in the responding lung metastases. TCR sequencing identified high T cell clonality in the lung metastases. The TCR repertoire showed low clonality in the heart and minimal overlap with the liver (1.2%), but some overlap with lung metastases (9.9%). Transcriptional profiling identified several potential mediators of increased inflammation in the heart. These findings provide new insights into the pathogenesis of autoimmune myocarditis with ipilimumab.

Citing Articles

The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.

Gamero M, Patel A, Storozynsky E Curr Cardiol Rep. 2024; 26(12):1487-1498.

PMID: 39441327 PMC: 11668830. DOI: 10.1007/s11886-024-02147-x.


Research Progress on Flavonoids in Traditional Chinese Medicine to Counteract Cardiotoxicity Associated with Anti-Tumor Drugs.

Shi H, Duan L, Tong L, Pu P, Wei L, Wang L Rev Cardiovasc Med. 2024; 25(3):74.

PMID: 39076949 PMC: 11263839. DOI: 10.31083/j.rcm2503074.


Immune myocarditis induced by sintilimab therapy: A case report.

Li Y, Zhai B, Yang B, Wang B, Wang Y, Qu M Exp Ther Med. 2024; 28(2):333.

PMID: 39006500 PMC: 11240266. DOI: 10.3892/etm.2024.12622.


Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.

Sharma A, Alexander G, Chu J, Markopoulos A, Maloul G, Ayub M J Am Heart Assoc. 2024; 13(10):e032620.

PMID: 38761070 PMC: 11179795. DOI: 10.1161/JAHA.123.032620.


Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.

Li M, He Y, Huang S, Hu X, Chen J Invest New Drugs. 2024; 42(1):116-126.

PMID: 38253746 DOI: 10.1007/s10637-024-01421-7.


References
1.
Cheng F, Loscalzo J . Autoimmune Cardiotoxicity of Cancer Immunotherapy. Trends Immunol. 2016; 38(2):77-78. DOI: 10.1016/j.it.2016.11.007. View

2.
Reuben A, Spencer C, Prieto P, Gopalakrishnan V, Reddy S, Miller J . Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMC: 5557036. DOI: 10.1038/s41525-017-0013-8. View

3.
Xu J, Brooks E . Giant Cell Myocarditis: A Brief Review. Arch Pathol Lab Med. 2016; 140(12):1429-1434. DOI: 10.5858/arpa.2016-0068-RS. View

4.
Kandolin R, Lehtonen J, Salmenkivi K, Raisanen-Sokolowski A, Lommi J, Kupari M . Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2012; 6(1):15-22. DOI: 10.1161/CIRCHEARTFAILURE.112.969261. View

5.
Cooper Jr L, Berry G, Shabetai R . Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997; 336(26):1860-6. DOI: 10.1056/NEJM199706263362603. View